{
    "info": {
        "nct_id": "NCT03045328",
        "official_title": "An Open Label Phase 2 Trial of Venetoclax With Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma",
        "inclusion_criteria": "* Subject must voluntarily sign and date an informed consent approved by the Institutional Review Board prior to initiation of any study specific procedures\n* Subject must have a diagnosis of CLL that meets International Workshop on Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute (NCI)-Working Group (WG) criteria\n* Subject must have relapsed/refractory disease with an indication for treatment according to the 2008 IWCLL/NCI WG criteria\n* Measurable nodal disease by computed tomography (CT)\n* Absolute neutrophil count > 750 cells/mm^3 (0.75 x 10^9/L)\n* Platelet count > 30,000 cells/mm^3 (30 x 10^9/L)\n* Hemoglobin > 8.0 g/dL\n* Serum aspartate transaminase (AST) or alanine transaminase (ALT) =< 2.5 x upper limit of normal (ULN)\n* Estimated creatinine clearance >= 30 mL/min (Cockcroft-Gault)\n* Bilirubin =< 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)\n* Prothrombin time/international normalized ratio (PT/INR) < 1.5 x ULN and partial thromboplastin time (PTT) (activated [a]PTT) < 1.5 x ULN\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2\n* Female subjects who are of non-reproductive potential (ie, post-menopausal by history - no menses for >= 1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy); female subjects of childbearing potential must have a negative serum pregnancy test upon study entry\n* Male and female subjects must agree to use highly effective methods of birth control (eg, condoms, implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], sexual abstinence, or sterilized partner) during the period of therapy and for 90 days after the last dose of study drug\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Subject has previously received either venetoclax or ibrutinib\n* Subject has received a live virus vaccine within 28 days prior to the initiation of study treatment\n* Subject has undergone an allogeneic stem cell transplant in the past 1 year and must not have active chronic graft versus host disease (cGVHD) if over 1 year post allogeneic transplant\n* Subject has developed Richter's transformation confirmed by biopsy\n* Chemotherapy =< 21 days prior to first administration of study treatment and/or monoclonal antibody =< 6 weeks prior to first administration of study treatment\n* History of other malignancies, except:\n\n  * Malignancy treated with curative intent and with no known active disease present for >= 3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\n  * Adequately treated carcinoma in situ without evidence of disease\n* Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc, or chronic administration [> 14 days] of > 20 mg/day of prednisone) within 28 days of the first dose of study drug\n* Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug\n* Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug\n* Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version [v]4), grade =< 1, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia\n* Known bleeding disorders (eg, von Willebrand's disease) or hemophilia\n* History of stroke or intracranial hemorrhage within 6 months prior to enrollment\n* Known history of human immunodeficiency virus (HIV) or active with hepatitis C virus (HCV) or hepatitis B virus (HBV); subjects who are positive for hepatitis B core antibody or hepatitis B surface antigen must have a negative polymerase chain reaction (PCR) result before enrollment; those who are PCR positive will be excluded\n* Any uncontrolled active systemic infection\n* Major surgery within 4 weeks of first dose of study drug\n* Any life threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk\n* Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization\n* Unable to swallow capsules or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction\n* Concomitant use of warfarin or other vitamin K antagonists\n* Requires treatment with a strong cytochrome P450 (CYP) 3A4/5 inhibitor\n* Lactating or pregnant\n* Unwilling or unable to participate in all required study evaluations and procedures\n* Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local subject privacy regulations)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Absolute neutrophil count > 750 cells/mm^3 (0.75 x 10^9/L)",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count > 750 cells/mm^3 (0.75 x 10^9/L)",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 750,
                                "unit": "cells/mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable nodal disease by computed tomography (CT)",
            "criterions": [
                {
                    "exact_snippets": "Measurable nodal disease",
                    "criterion": "nodal disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "by computed tomography (CT)",
                    "criterion": "nodal disease assessment method",
                    "requirements": [
                        {
                            "requirement_type": "assessment method",
                            "expected_value": "computed tomography (CT)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count > 30,000 cells/mm^3 (30 x 10^9/L)",
            "criterions": [
                {
                    "exact_snippets": "Platelet count > 30,000 cells/mm^3 (30 x 10^9/L)",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 30000,
                                "unit": "cells/mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject must have a diagnosis of CLL that meets International Workshop on Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute (NCI)-Working Group (WG) criteria",
            "criterions": [
                {
                    "exact_snippets": "diagnosis of CLL",
                    "criterion": "chronic lymphocytic leukemia (CLL) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "meets International Workshop on Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute (NCI)-Working Group (WG) criteria",
                    "criterion": "IWCLL/NCI-WG criteria for CLL",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject must have relapsed/refractory disease with an indication for treatment according to the 2008 IWCLL/NCI WG criteria",
            "criterions": [
                {
                    "exact_snippets": "Subject must have relapsed/refractory disease",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "indication for treatment according to the 2008 IWCLL/NCI WG criteria",
                    "criterion": "indication for treatment per 2008 IWCLL/NCI WG criteria",
                    "requirements": [
                        {
                            "requirement_type": "meets criteria",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject must voluntarily sign and date an informed consent approved by the Institutional Review Board prior to initiation of any study specific procedures",
            "criterions": [
                {
                    "exact_snippets": "Subject must voluntarily sign and date an informed consent approved by the Institutional Review Board",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed and dated",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "voluntary",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "IRB approval",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior to initiation of any study specific procedures",
                    "criterion": "timing of informed consent",
                    "requirements": [
                        {
                            "requirement_type": "before study procedures",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin > 8.0 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin > 8.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 8.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum aspartate transaminase (AST) or alanine transaminase (ALT) =< 2.5 x upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Serum aspartate transaminase (AST) ... =< 2.5 x upper limit of normal (ULN)",
                    "criterion": "serum aspartate transaminase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine transaminase (ALT) =< 2.5 x upper limit of normal (ULN)",
                    "criterion": "alanine transaminase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Estimated creatinine clearance >= 30 mL/min (Cockcroft-Gault)",
            "criterions": [
                {
                    "exact_snippets": "Estimated creatinine clearance >= 30 mL/min (Cockcroft-Gault)",
                    "criterion": "estimated creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bilirubin =< 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)",
            "criterions": [
                {
                    "exact_snippets": "Bilirubin =< 1.5 x ULN",
                    "criterion": "bilirubin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless bilirubin rise is due to Gilbert's syndrome",
                    "criterion": "bilirubin rise due to Gilbert's syndrome",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unless bilirubin rise is ... of non-hepatic origin",
                    "criterion": "bilirubin rise of non-hepatic origin",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1",
                                "2"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prothrombin time/international normalized ratio (PT/INR) < 1.5 x ULN and partial thromboplastin time (PTT) (activated [a]PTT) < 1.5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Prothrombin time/international normalized ratio (PT/INR) < 1.5 x ULN",
                    "criterion": "prothrombin time/international normalized ratio (PT/INR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "partial thromboplastin time (PTT) (activated [a]PTT) < 1.5 x ULN",
                    "criterion": "partial thromboplastin time (PTT) (activated [a]PTT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male and female subjects must agree to use highly effective methods of birth control (eg, condoms, implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], sexual abstinence, or sterilized partner) during the period of therapy and for 90 days after the last dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Male and female subjects must agree to use highly effective methods of birth control (eg, condoms, implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], sexual abstinence, or sterilized partner) during the period of therapy and for 90 days after the last dose of study drug",
                    "criterion": "use of highly effective birth control methods",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "methods",
                            "expected_value": [
                                "condoms",
                                "implants",
                                "injectables",
                                "combined oral contraceptives",
                                "some intrauterine devices (IUDs)",
                                "sexual abstinence",
                                "sterilized partner"
                            ]
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during the period of therapy and for 90 days after the last dose of study drug"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female subjects who are of non-reproductive potential (ie, post-menopausal by history - no menses for >= 1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy); female subjects of childbearing potential must have a negative serum pregnancy test upon study entry",
            "criterions": [
                {
                    "exact_snippets": "Female subjects who are of non-reproductive potential (ie, post-menopausal by history - no menses for >= 1 year",
                    "criterion": "menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "menopausal state",
                            "expected_value": "post-menopausal"
                        },
                        {
                            "requirement_type": "absence of menses duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "history of hysterectomy",
                    "criterion": "hysterectomy history",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of bilateral tubal ligation",
                    "criterion": "bilateral tubal ligation history",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of bilateral oophorectomy",
                    "criterion": "bilateral oophorectomy history",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "female subjects of childbearing potential must have a negative serum pregnancy test upon study entry",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Chemotherapy =< 21 days prior to first administration of study treatment and/or monoclonal antibody =< 6 weeks prior to first administration of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Chemotherapy =< 21 days prior to first administration of study treatment",
                    "criterion": "chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "monoclonal antibody =< 6 weeks prior to first administration of study treatment",
                    "criterion": "monoclonal antibody",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has developed Richter's transformation confirmed by biopsy",
            "criterions": [
                {
                    "exact_snippets": "Subject has developed Richter's transformation",
                    "criterion": "Richter's transformation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmed by biopsy",
                    "criterion": "biopsy confirmation of Richter's transformation",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug",
                    "criterion": "vaccination with live, attenuated vaccines",
                    "requirements": [
                        {
                            "requirement_type": "time since vaccination",
                            "expected_value": {
                                "operator": "<",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug",
                    "criterion": "recent infection requiring systemic treatment",
                    "requirements": [
                        {
                            "requirement_type": "completion interval before first dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Requires treatment with a strong cytochrome P450 (CYP) 3A4/5 inhibitor",
            "criterions": [
                {
                    "exact_snippets": "Requires treatment with a strong cytochrome P450 (CYP) 3A4/5 inhibitor",
                    "criterion": "treatment with strong CYP3A4/5 inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "requirement for treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known bleeding disorders (eg, von Willebrand's disease) or hemophilia",
            "criterions": [
                {
                    "exact_snippets": "Known bleeding disorders (eg, von Willebrand's disease)",
                    "criterion": "bleeding disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hemophilia",
                    "criterion": "hemophilia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any uncontrolled active systemic infection",
            "criterions": [
                {
                    "exact_snippets": "Any uncontrolled active systemic infection",
                    "criterion": "systemic infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Lactating or pregnant",
            "criterions": [
                {
                    "exact_snippets": "Lactating",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of other malignancies, except:",
            "criterions": [
                {
                    "exact_snippets": "History of other malignancies",
                    "criterion": "history of other malignancies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease",
            "criterions": [
                {
                    "exact_snippets": "Adequately treated non-melanoma skin cancer",
                    "criterion": "non-melanoma skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "lentigo maligna without evidence of disease",
                    "criterion": "lentigo maligna",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": "without evidence of disease"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any life threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk",
            "criterions": [
                {
                    "exact_snippets": "Any life threatening illness, medical condition, or organ system dysfunction",
                    "criterion": "life threatening illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Any life threatening illness, medical condition, or organ system dysfunction",
                    "criterion": "medical condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Any life threatening illness, medical condition, or organ system dysfunction",
                    "criterion": "organ system dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk",
                    "criterion": "investigator's opinion of risk to safety or study outcomes",
                    "requirements": [
                        {
                            "requirement_type": "risk assessment",
                            "expected_value": "could compromise the subject's safety or put the study outcomes at undue risk"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of stroke or intracranial hemorrhage within 6 months prior to enrollment",
            "criterions": [
                {
                    "exact_snippets": "History of stroke ... within 6 months prior to enrollment",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... intracranial hemorrhage within 6 months prior to enrollment",
                    "criterion": "intracranial hemorrhage",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of human immunodeficiency virus (HIV) or active with hepatitis C virus (HCV) or hepatitis B virus (HBV); subjects who are positive for hepatitis B core antibody or hepatitis B surface antigen must have a negative polymerase chain reaction (PCR) result before enrollment; those who are PCR positive will be excluded",
            "criterions": [
                {
                    "exact_snippets": "Known history of human immunodeficiency virus (HIV)",
                    "criterion": "human immunodeficiency virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "active with hepatitis C virus (HCV)",
                    "criterion": "hepatitis C virus (HCV) infection",
                    "requirements": [
                        {
                            "requirement_type": "active infection",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "active with ... hepatitis B virus (HBV)",
                    "criterion": "hepatitis B virus (HBV) infection",
                    "requirements": [
                        {
                            "requirement_type": "active infection",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects who are positive for hepatitis B core antibody or hepatitis B surface antigen must have a negative polymerase chain reaction (PCR) result before enrollment; those who are PCR positive will be excluded",
                    "criterion": "hepatitis B virus (HBV) PCR result in subjects positive for hepatitis B core antibody or hepatitis B surface antigen",
                    "requirements": [
                        {
                            "requirement_type": "PCR result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has previously received either venetoclax or ibrutinib",
            "criterions": [
                {
                    "exact_snippets": "previously received ... venetoclax",
                    "criterion": "venetoclax treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "previously received ... ibrutinib",
                    "criterion": "ibrutinib treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery within 4 weeks of first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 4 weeks of first dose of study drug",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Malignancy treated with curative intent and with no known active disease present for >= 3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician",
            "criterions": [
                {
                    "exact_snippets": "Malignancy treated with curative intent",
                    "criterion": "malignancy",
                    "requirements": [
                        {
                            "requirement_type": "treatment_intent",
                            "expected_value": "curative"
                        }
                    ]
                },
                {
                    "exact_snippets": "no known active disease present for >= 3 years before the first dose of study drug",
                    "criterion": "active disease",
                    "requirements": [
                        {
                            "requirement_type": "absence_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "felt to be at low risk for recurrence by treating physician",
                    "criterion": "risk of recurrence",
                    "requirements": [
                        {
                            "requirement_type": "risk_level",
                            "expected_value": "low"
                        },
                        {
                            "requirement_type": "assessed_by",
                            "expected_value": "treating physician"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has received a live virus vaccine within 28 days prior to the initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "received a live virus vaccine within 28 days prior to the initiation of study treatment",
                    "criterion": "live virus vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<",
                                "value": 28,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "vaccine type",
                            "expected_value": "live virus"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequately treated carcinoma in situ without evidence of disease",
            "criterions": [
                {
                    "exact_snippets": "Adequately treated carcinoma in situ",
                    "criterion": "carcinoma in situ",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "without evidence of disease",
                    "criterion": "evidence of disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unwilling or unable to participate in all required study evaluations and procedures",
            "criterions": [
                {
                    "exact_snippets": "Unwilling ... to participate in all required study evaluations and procedures",
                    "criterion": "willingness to participate in study evaluations and procedures",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unable to participate in all required study evaluations and procedures",
                    "criterion": "ability to participate in study evaluations and procedures",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local subject privacy regulations)",
            "criterions": [
                {
                    "exact_snippets": "Unable to understand the purpose and risks of the study",
                    "criterion": "understanding of study purpose and risks",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "to provide a signed and dated informed consent form (ICF)",
                    "criterion": "informed consent form",
                    "requirements": [
                        {
                            "requirement_type": "signed and dated",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "authorization to use protected health information (in accordance with national and local subject privacy regulations)",
                    "criterion": "authorization to use protected health information",
                    "requirements": [
                        {
                            "requirement_type": "authorization",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concomitant use of warfarin or other vitamin K antagonists",
            "criterions": [
                {
                    "exact_snippets": "Concomitant use of warfarin",
                    "criterion": "warfarin use",
                    "requirements": [
                        {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Concomitant use of ... other vitamin K antagonists",
                    "criterion": "vitamin K antagonist use",
                    "requirements": [
                        {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version [v]4), grade =< 1, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia",
            "criterions": [
                {
                    "exact_snippets": "Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version [v]4), grade =< 1, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia",
                    "criterion": "toxicities from prior anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "resolution",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "CTCAE v4 grade"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "alopecia"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc, or chronic administration [> 14 days] of > 20 mg/day of prednisone) within 28 days of the first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc, or chronic administration [> 14 days] of > 20 mg/day of prednisone) within 28 days of the first dose of study drug",
                    "criterion": "systemic immunosuppressant therapy",
                    "requirements": [
                        {
                            "requirement_type": "concurrent use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "examples",
                            "expected_value": [
                                "cyclosporine A",
                                "tacrolimus"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic administration [> 14 days] of > 20 mg/day of prednisone",
                    "criterion": "prednisone administration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 20,
                                "unit": "mg/day"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has undergone an allogeneic stem cell transplant in the past 1 year and must not have active chronic graft versus host disease (cGVHD) if over 1 year post allogeneic transplant",
            "criterions": [
                {
                    "exact_snippets": "Subject has undergone an allogeneic stem cell transplant in the past 1 year",
                    "criterion": "allogeneic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since transplant",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must not have active chronic graft versus host disease (cGVHD) if over 1 year post allogeneic transplant",
                    "criterion": "active chronic graft versus host disease (cGVHD)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time since allogeneic transplant",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unable to swallow capsules or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction",
            "criterions": [
                {
                    "exact_snippets": "Unable to swallow capsules",
                    "criterion": "ability to swallow capsules",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "malabsorption syndrome",
                    "criterion": "malabsorption syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "disease significantly affecting gastrointestinal function",
                    "criterion": "disease affecting gastrointestinal function",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "resection of the stomach or small bowel",
                    "criterion": "resection of the stomach or small bowel",
                    "requirements": [
                        {
                            "requirement_type": "history of resection",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic inflammatory bowel disease",
                    "criterion": "symptomatic inflammatory bowel disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "ulcerative colitis",
                    "criterion": "ulcerative colitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "partial or complete bowel obstruction",
                    "criterion": "bowel obstruction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization",
            "criterions": [
                {
                    "exact_snippets": "Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification",
                    "criterion": "cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "currently active"
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled arrhythmia",
                    "criterion": "arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": [
                                "3",
                                "4"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "history within time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to randomization"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "history within time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to randomization"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization",
                    "criterion": "acute coronary syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history within time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to randomization"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}